Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNXNASDAQ:IGMSNASDAQ:PROKNASDAQ:TERN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$2.47-8.5%$3.16$2.30▼$8.40$270.98M1.141.77 million shs1.18 million shsIGMSIGM Biosciences$1.26$1.44$1.15▼$22.50$75.32M0.37341,365 shs157,091 shsPROKProKidney$1.01-1.0%$1.39$0.87▼$4.44$294.58M1.38658,105 shs241,386 shsTERNTerns Pharmaceuticals$3.32-5.4%$3.98$3.08▼$11.40$282.00M-0.31.40 million shs803,634 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon+12.50%-1.82%-3.91%-48.37%-60.29%IGMSIGM Biosciences+5.88%+2.44%-8.70%-80.31%-87.76%PROKProKidney+6.23%-1.92%-32.00%-42.70%-27.14%TERNTerns Pharmaceuticals+4.78%+8.00%-12.47%-39.48%-46.82%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANNXAnnexon1.663 of 5 stars3.51.00.00.01.11.70.6IGMSIGM Biosciences4.5119 of 5 stars4.02.00.04.61.53.31.3PROKProKidney1.6211 of 5 stars3.30.00.00.01.92.50.6TERNTerns Pharmaceuticals4.1683 of 5 stars3.32.00.04.12.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 3.00Buy$15.80539.68% UpsideIGMSIGM Biosciences 1.90Reduce$5.50336.51% UpsidePROKProKidney 2.50Moderate Buy$5.00395.05% UpsideTERNTerns Pharmaceuticals 2.67Moderate Buy$18.30451.20% UpsideCurrent Analyst Ratings BreakdownLatest IGMS, TERN, PROK, and ANNX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/4/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/28/2025TERNTerns PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageMarket Perform1/13/2025IGMSIGM BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Neutral1/10/2025IGMSIGM BiosciencesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$48.00 ➝ $2.001/10/2025IGMSIGM BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$12.00 ➝ $2.001/10/2025IGMSIGM BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$22.00 ➝ $3.001/10/2025IGMSIGM BiosciencesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeEqual Weight ➝ Underweight$12.00 ➝ $2.001/10/2025IGMSIGM BiosciencesStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$27.00 ➝ $2.501/10/2025IGMSIGM BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$20.00 ➝ $1.501/10/2025IGMSIGM BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/AIGMSIGM Biosciences$2.68M28.11N/AN/A$3.46 per share0.36PROKProKidney$76K3,876.03N/AN/A($4.84) per share-0.21TERNTerns PharmaceuticalsN/AN/AN/AN/A$4.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$134.24M-$1.02N/AN/AN/AN/A-38.99%-33.90%3/25/2025 (Estimated)IGMSIGM Biosciences-$246.42M-$3.24N/AN/AN/A-7,534.03%-155.42%-61.04%5/6/2025 (Estimated)PROKProKidney-$35.47M-$0.63N/AN/AN/AN/AN/A-10.24%5/9/2025 (Estimated)TERNTerns Pharmaceuticals-$90.21M-$1.18N/AN/AN/AN/A-32.76%-31.33%5/12/2025 (Estimated)Latest IGMS, TERN, PROK, and ANNX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/25/2025N/AANNXAnnexon-$0.28N/AN/AN/AN/AN/A3/20/2025Q4 2024TERNTerns Pharmaceuticals-$0.30-$0.24+$0.06-$0.24N/AN/A3/17/2025Q4 2024PROKProKidney-$0.14-$0.17-$0.03-$0.17N/A$0.08 million3/6/2025Q4 2024IGMSIGM Biosciences-$0.74-$0.61+$0.13-$0.61$0.39 million$0.41 million3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AIGMSIGM BiosciencesN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATERNTerns PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A17.1717.18IGMSIGM BiosciencesN/A5.225.22PROKProKidneyN/A17.0817.09TERNTerns PharmaceuticalsN/A32.9932.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AIGMSIGM Biosciences42.79%PROKProKidney51.59%TERNTerns Pharmaceuticals98.26%Insider OwnershipCompanyInsider OwnershipANNXAnnexon12.67%IGMSIGM Biosciences57.00%PROKProKidney41.49%TERNTerns Pharmaceuticals15.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60109.71 million93.09 millionOptionableIGMSIGM Biosciences19059.78 million25.57 millionOptionablePROKProKidney3291.66 million170.65 millionOptionableTERNTerns Pharmaceuticals4084.94 million72.11 millionNot OptionableIGMS, TERN, PROK, and ANNX HeadlinesRecent News About These CompaniesTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMarch 25 at 4:24 AM | marketbeat.comOppenheimer Remains a Buy on Terns Pharmaceuticals (TERN)March 25 at 12:37 AM | markets.businessinsider.comTerns Pharmaceuticals' (TERN) Market Perform Rating Reiterated at William BlairMarch 24 at 1:35 AM | americanbankingnews.comWilliam Blair Reaffirms Market Perform Rating for Terns Pharmaceuticals (NASDAQ:TERN)March 22 at 12:18 PM | marketbeat.comWilliam Blair Reaffirms Their Hold Rating on Terns Pharmaceuticals (TERN)March 22 at 2:30 AM | markets.businessinsider.comTerns Pharmaceuticals Reports 2024 Progress and OutlookMarch 22 at 12:32 AM | tipranks.comTerns Pharmaceuticals (NASDAQ:TERN) Releases Quarterly Earnings Results, Beats Estimates By $0.06 EPSMarch 21, 2025 | marketbeat.comWhy Terns Pharmaceuticals, Inc.’s (TERN) Stock Is Up 14.97%March 21, 2025 | aaii.comTerns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesMarch 20, 2025 | globenewswire.comThis Weight Loss Stock Could Skyrocket by 462%, According to Wall StreetMarch 9, 2025 | fool.comCandriam S.C.A. Buys New Position in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)March 8, 2025 | marketbeat.comTerns Pharmaceuticals (TERN) Projected to Post Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comTerns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Rating of "Moderate Buy" by AnalystsMarch 1, 2025 | marketbeat.comWilliam Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)March 1, 2025 | marketbeat.comTerns Pharmaceuticals initiated with a Market Perform at William BlairMarch 1, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform RecommendationMarch 1, 2025 | msn.comAnalysts Offer Insights on Healthcare Companies: Vericel (VCEL) and Terns Pharmaceuticals (TERN)February 27, 2025 | markets.businessinsider.comIts CEO died. The company scrapped a promising program. Now, for their 2nd act.February 26, 2025 | finance.yahoo.comTerns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)February 26, 2025 | globenewswire.comTerns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial OfficerFebruary 25, 2025 | finanznachrichten.deTerns Pharmaceuticals sees cash runway into 2028February 25, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesVolatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsBy Gabriel Osorio-Mazilli | February 27, 2025View Volatility Is Back: 3 Stocks To Cushion the S&P 500's SwingsSuper Micro's International Presence Makes It a Winning StockBy Gabriel Osorio-Mazilli | March 17, 2025View Super Micro's International Presence Makes It a Winning Stock3 Tech Stocks Defying Sector Weakness and Thriving in 2025By Leo Miller | March 10, 2025View 3 Tech Stocks Defying Sector Weakness and Thriving in 2025How to Build the Ultimate Everything ETF PortfolioBy Jeffrey Neal Johnson | March 16, 2025View How to Build the Ultimate Everything ETF PortfolioRobinhood's Rally: Is Global Expansion the Next Big Catalyst?By Leo Miller | March 6, 2025View Robinhood's Rally: Is Global Expansion the Next Big Catalyst?IGMS, TERN, PROK, and ANNX Company DescriptionsAnnexon NASDAQ:ANNX$2.47 -0.23 (-8.52%) Closing price 04:00 PM EasternExtended Trading$2.56 +0.09 (+3.64%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.IGM Biosciences NASDAQ:IGMS$1.26 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.24 -0.02 (-1.98%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.ProKidney NASDAQ:PROK$1.01 -0.01 (-0.98%) Closing price 04:00 PM EasternExtended Trading$1.01 0.00 (-0.10%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Terns Pharmaceuticals NASDAQ:TERN$3.32 -0.19 (-5.41%) Closing price 04:00 PM EasternExtended Trading$3.45 +0.13 (+4.04%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Insiders Sell: This Is What It Means for the Market Oklo’s Stock Price Meltdown Is an Opportunity to Buy Top Dividend Stocks With Over 10 Years of Hikes—and Room to Grow Quantum Gamble? Is IonQ's Stock an Opportunity or a Mirage? Will CrowdStrike's FedRAMP Authorization Move CRWD Stock? Top 3 Insider Stock Buys in March—Are They Still Good in April? Taiwan Semiconductor Attracts Big Money on NVIDIA Chip Growth D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
